Reducing plasma cholesterol is not the end of the quest.
Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave., Los Angeles, CA 90095-1679, USA. mnavab@mednet.ucla.edu
Mohamad
M
Navab
Maryam
M
Shabihkhani
Kaveh Daniel
KD
Navab
Samra
S
Vazirian
Maryam
M
Haghnegahdar
Srinivasa T
ST
Reddy
D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism*; D050197:Atherosclerosis / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D011973:Receptors, LDL / Q000235:genetics*
C478448:Ac-hE18A-NH(2); D001057:Apolipoproteins E; D008074:Lipoproteins; D010446:Peptide Fragments; D010455:Peptides; D011973:Receptors, LDL; C582615:mR18L peptide